Cancer cells often exhibit dysregulated cell cycles, allowing unchecked division. Targeting cell cycle regulators like cyclin-dependent kinases (CDKs) can halt cancer progression. CDK inhibitors such as palbociclib are used to treat certain types of breast cancer by blocking the action of these enzymes.
